Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors
2018; American Society for Microbiology; Volume: 86; Issue: 9 Linguagem: Inglês
10.1128/iai.00114-18
ISSN1098-5522
AutoresErwan Atcheson, Karolis Bauza, Ahmed M. Salman, Eduardo Rodrigues Alves, Joshua Blight, Martha Eva Viveros‐Sandoval, Chris J. Janse, Shahid M. Khan, Adrian V. S. Hill, Arturo Reyes‐Sandoval,
Tópico(s)Mosquito-borne diseases and control
ResumoVivax malaria remains one of the most serious and neglected tropical diseases, with 132 to 391 million clinical cases per year and 2.5 billion people at risk of infection. A vaccine against Plasmodium vivax could have more impact than any other intervention, and the use of a vaccine targeting multiple antigens may result in higher efficacy against sporozoite infection than targeting a single antigen.
Referência(s)